Clinical Trial Search

Primary: Acute Toxicity Rate — 6 percentage of participants

Primary: Morphine Equivalent Usage While in the Hospital — 29.59; 30.82; 10.54; 11.74 mg

Primary: Diagnostic Yield — 81; 25 participants

Primary: Ovulation in Cycle 2 — 3; 2 Participants

Primary: Number of Participants Prescribed Appropriate Treatment — 61; 104; 58; 21 Participants — p=<.001

Primary: Proportion of Female Respondents Having Their Preferences Based on Physician Gender for the OB/GYN Care — 667; 87; 261 Participants

Primary: Clinical Cure Rate — 18 Participants

Primary: Clinical Cure Rate at Day 7-14 — 10; 16 Participants

Primary: The i) Percent Sensitivity and ii) Percent Specificity of Click Device for Detection of Chlamydia Trachomatis (CT) in Self-collected Vaginal Specimens as Compared to PIS…

Primary: Menstrual Blood Loss (MBL) as Measured by Pictorial Blood Loss Assessment Chart (PBLAC). — 15; 0 units on a scale — p=0.003

Primary: Successful Removal of the Uterus Without Conversion to Another Technique — 35; 35 Participants — p=0.0221

Primary: Total Testosterone — 1.5; 2.9 nmol/L — p=<0.05

Primary: Patient Reported Satisfaction — 54; 55 satisfaction score at baseline

Primary: Hot Flush Frequency Total Score (HFRS) Change — 9.3; 8.8; 12.7 score on a scale

Primary: Anxiety Score for Patients Attending Clinic — 6 score on a scale

Primary: Clinical Cure Rate — 9 Participants

Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L

Primary: Percentage of Participants Who Underwent Gynecologic Surgery — 42; 32; 26 percentage of participants

Primary: Percentage of Subjects Who Are in Amenorrhea at the End of All Four Treatment Courses — 48.7; 60.5 percentage of subjects

Primary: Mean Antibiotic Days of Therapy (DOT) Administered Per Patient With Symptomatic Urethritis or Cervicitis — 7; 1 Antibiotic days of therapy (DOT) — p=0.053

Primary: One-year Incidence of Chlamydial and Gonococcal Infections in Women Who Receive Screening (Every 2 Months) and Treatment for Asymptomatic Bacterial Vaginosis as Compared…

Primary: Toxicity Rates of Patients Treated With Concurrent Avastin and Daily Pelvic Radiation With no Other Concurrent Chemotherapy — 766 Events

Primary: Percentage of Subjects With Reduction of Uterine Bleeding at Week 13 Visit Defined as Pictorial Blood-loss Assessment Chart (PBAC) Score < 75 at End-of-treatment Visit…

Primary: Mean Doses Given — 93.9; 63.2; 58.63 Gy

Primary: Percentage of Subjects Showing Unfavorable Changes in Primary Microflora — 52.7; 52.9; 60.0 Percentage of Participants

Primary: All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight — 2.82; 2.46; 4.54…

Primary: Changes in the Sizes (mm) of Endometrioma, Deep Infiltrating Endometriosis (DIE) and Adenomyosis Lesions Summed by Type on Magnetic Resonance (MR) Images at Cycle 4…

Primary: Urinary Tract Infections — 18; 10 participants

Primary: Safety (Adverse Events) — 0 device related adverse event

Primary: Patient Global Impression of Improvement (PGI-I) Score at 4 Weeks After Initial Treatment — 2.66 score on a scale